Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03860857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarker Exploration in Aging, Cognition and Neurodegeneration

Study acronym: BEACoN
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updated Publications: details revised at 5 of 5 entriesv7 Show 1 more changeShow less
    • Publications: details revised at 5 of 5 entries
  2. Enrollment target: 200 to 300 Site contact updated · Publications expanded, about 215 wordsv6 Show 2 more changesShow less
    • Site contact updated
    • Publications expanded, about 215 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Dec 22, 2023 to Dec 22, 2026 Completion date: Dec 22, 2024 to Dec 22, 2027 · Eligibility criteria expanded, about 16 words · Study title shortened, about 3 wordsv5 Show 3 more changesShow less
    • Completion date: Dec 22, 2024 to Dec 22, 2027
    • Eligibility criteria expanded, about 16 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Site contact updated Eligibility criteria shortened, about 1 wordv4 Show 1 more changeShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Site contact updatedv3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
Trial Details
NCT Number NCT03860857
Lead Sponsor University of California, Irvine
Collaborators: National Institute on Aging (NIA)
Conditions Alzheimer Disease, Cognitive Impairment, Cognitive Decline
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov